Skip Navigation LinksHome > September 2013 - Volume 23 - Issue 7 > Patterns of Recurrence in Patients Treated With Bevacizumab...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e31829f17c9
Ovarian Cancer

Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer

Rauh-Hain, Jose Alejandro MD*; Guseh, Stephanie H. MD*†; Esselen, Katharine M. MD, MBA; Growdon, Whitfield B. MD*; Schorge, John O. MD*; Horowitz, Neil S. MD; Krasner, Carolyn N. MD; del Carmen, Marcela G. MD, MPH*; Birrer, Michael J. MD, PhD; Dizon, Don S. MD

Collapse Box

Abstract

Objective: The purpose of this study was to compare the distribution of the first site of recurrence in patients with epithelial ovarian cancer (EOC) who received first-line treatment with bevacizumab compared with patients who did not receive bevacizumab.

Methods: From the Cancer Registry database at our institutions, we identified a group of patients with recurrent EOC who underwent treatment from January 1, 2005, to December 31, 2010. Each patient record was evaluated to classify the site of first recurrence. Correlation between categorical variables was assessed with χ2 test.

Results: Two hundred ninety-two patients with advanced EOC (stage III or IV) who originally responded to chemotherapy and had a recurrence were identified. Of these, 37 (12.5%) had received postoperative chemotherapy bevacizumab, and 255 (87.5%) did not. Compared with those not treated with bevacizumab, there was a lower incidence of liver recurrence (0% vs 9%; P = 0.05) and a higher rate of lung and/or pleural recurrence (22% vs 5%; P = 0.001) and recurrence at distant sites (22% vs 9%; P = 0.03) in patients who received bevacizumab. There was no difference in the incidence of ascites at the time of recurrence between these groups.

Conclusions: Patients who received bevacizumab as part of primary treatment for EOC had a higher rate of lung and/or pleural recurrence and a lower rate of liver recurrence. There was no difference in the rate of ascites at the time of recurrence.

© 2013 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.